Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional ...

REGIONS NEWS - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen ...

Acanthomatous ameloblastoma: This is usually just an oral tumor in dogs, but it can cause swelling of the jaw. It will almost ...

Knowledge of the association between HPV and oropharyngeal squamous cell carcinoma is poor and did not improve from 2018 to 2020.

Survivors of blood or marrow transplant (BMT) face a significant risk of developing cutaneous malignant neoplasms, including ...

See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

The chef was able to ring the victory bell to mark the end of her cancer treatment and is getting her tastebuds back. Here's what to know about tongue cancer.

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...

First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.